



Press release - regulated information

Information on the total number of voting rights and shares

Ghent, BELGIUM – 13 October 2026, 18:00 CEST – [Biotalys NV](#) (hereafter the “**Company**” or “**Biotalys**”) today announces in accordance with article 15 of the Belgian Act of 2 May 2007 on the disclosure of major shareholdings (the “**Belgian Act**”), that the outstanding share capital and outstanding voting securities of the Company can be summarised as follows:

- Share capital: EUR 6,720,420.45 EUR
- Total number of securities carrying voting rights: 45,448,940 (all ordinary shares)
- Total number of voting rights (= denominator): 45,448,940 (all relating to ordinary shares)
- Number of rights to subscribe for securities carrying voting rights not yet issued:
 - 1,779,400 “ESOP Warrants”, entitling their holders to subscribe for a total number of 1,779,400 profit certificates which will, if and when issued, automatically convert into a total number of maximum 889,700 securities carrying voting rights (all ordinary shares).
 - 1,248,660 “ESOP Warrants”, entitling their holders to subscribe for a total number of maximum 1,248,660 securities carrying voting rights (all ordinary shares).
 - 25,511 share units, awarded in aggregate to the independent directors of the Company in the framework of its remuneration policy. Each share unit contains the obligation to subscribe to one new share of the Company at an issue price of one EUR per share-unit. Cash settlement is possible. The conditions of the share units are described in the remuneration policy of the Company.
- The Company has no outstanding convertible bonds or non-voting shares.

The change in the capital, outstanding shares and voting rights resulted from an issue of 4,484 shares at an issue price of one EUR per share through the authorised capital following the conversion of share-units granted to independent directors in accordance with the remuneration policy of the Company. Pursuant to article 16 of the Royal Decree of 14 November 2007, the report of the board of directors and the auditor in connection with the issue of these shares within the authorised capital is available on the website of the Company.

Pursuant to the Belgian Act, a notification to the Company and the Belgian Financial Services and Markets Authority (FSMA) is required by all natural and legal persons in each case where the percentage of voting rights attached to the securities held by such persons in the Company reaches, exceeds or falls below the threshold of 5%, 10%, and every subsequent multiple of 5%, of the total number of voting rights in the Company.

For further information, please contact:

Toon Musschoot, Investor Relations & Communication

T: +32 (0)9 274 54 00

E: IR@biotalys.com

About Biotalys

Biotalys is an Agricultural Technology (AgTech) company developing precision biocontrol solutions based on proteins for the protection of crops in both the pre- and post-harvest markets. The company provides novel solutions that bridge the efficacy and scale of chemistry with the environmental advantages of biological solutions. Based on its novel AGROBODY® technology platform, Biotalys is developing a strong and diverse pipeline of effective product candidates with a favorable safety profile that aim to address key crop pests and diseases across the whole value chain, from soil to plate. Biotalys was founded in 2013 as a spin-off from the VIB (Flanders Institute for Biotechnology) and is listed on Euronext Brussels. The company is based in the biotech cluster in Ghent, Belgium. More information can be found on www.biotalys.com.

Important Notice

Biotalys, its business, prospects and financial position remain exposed and subject to risks and uncertainties. A description of and reference to these risks and uncertainties can be found in the annual report on the consolidated annual accounts published on the company's website.

